Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy male and/or female subjects between the ages of 18 and 55 years
Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 and a total body weight \>50 kg (110 lbs)
Nonsmoker or smoker of fewer than 5 cigarettes per day as determined by history
An informed consent document signed and dated by the subject
You may not be if
History of significant blood, kidney, endocrine, lung, gastrointestinal, heart, liver, psychiatric, neurologic, or allergic disease
History of seizure disorder
Presence or history of glaucoma or increased intraocular pressure
Allergy to or unable to tolerate aripiprazole, desvenlafaxine, or venlafaxine
History of substance abuse within 1 year of study
A positive urine drug screen
Treatment with an investigational drug within 30 days
Consumption of grapefruit or grapefruit related citrus fruits
12 lead ECG demonstrating QTc \>450 msec at screening
Pregnant or nursing females
Use of prescription or nonprescription drugs and dietary supplements
History of sensitivity to heparin or heparin induced thrombocytopenia
Severe acute or chronic medical or psychiatric condition or laboratory abnormality
Clareo Health | Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects
